{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma%2C+Recurrent+High+Grade&page=4", "query": { "condition": "Glioma, Recurrent High Grade", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 229, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma%2C+Recurrent+High+Grade&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma%2C+Recurrent+High+Grade&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T21:30:57.277Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00006246", "title": "Busulfan in Treating Children and Adolescents With Refractory CNS Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Leukemia", "Lymphoma", "Metastatic Cancer", "Retinoblastoma", "Sarcoma" ], "interventions": [ { "name": "busulfan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pediatric Brain Tumor Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 28, "start_date": "2000-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-10-07", "last_synced_at": "2026-10-07T21:30:57.277Z", "location_count": 8, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006246" }, { "nct_id": "NCT02168270", "title": "Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Anaplastic Oligoastrocytoma", "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "ascorbic acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "quality-of-life assessment", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "OTHER" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 4, "start_date": "2014-06-16", "completion_date": "2015-08-20", "has_results": true, "last_update_posted_date": "2023-11-24", "last_synced_at": "2026-10-07T21:30:57.277Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02168270" }, { "nct_id": "NCT01081223", "title": "Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioma", "High Grade Astrocytoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "Cancer vaccine plus immune adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "TVAX Biomedical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2010-04", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2023-06-01", "last_synced_at": "2026-10-07T21:30:57.277Z", "location_count": 1, "location_summary": "Kansas City, Missouri", "locations": [ { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01081223" }, { "nct_id": "NCT05561374", "title": "Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "High-grade Glioma", "Oligodendroglioma", "Astrocytoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "Low-dose OKN-007, BID", "type": "DRUG" }, { "name": "Low-dose OKN-007, TID", "type": "DRUG" }, { "name": "Mid-dose OKN-007, TID", "type": "DRUG" }, { "name": "High-dose OKN-007, TID", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oblato, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2023-04-17", "completion_date": "2025-06-30", "has_results": false, "last_update_posted_date": "2024-11-29", "last_synced_at": "2026-10-07T21:30:57.277Z", "location_count": 4, "location_summary": "Santa Monica, California • Louisville, Kentucky • Winston-Salem, North Carolina + 1 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT05561374" }, { "nct_id": "NCT00769093", "title": "Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Neoplasms" ], "interventions": [ { "name": "Ferumoxytol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 6, "start_date": "2008-10", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2017-04-21", "last_synced_at": "2026-10-07T21:30:57.277Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00769093" }, { "nct_id": "NCT02359565", "title": "Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Constitutional Mismatch Repair Deficiency Syndrome", "Lynch Syndrome", "Malignant Glioma", "Recurrent Brain Neoplasm", "Recurrent Childhood Ependymoma", "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Medulloblastoma", "Refractory Brain Neoplasm", "Refractory Diffuse Intrinsic Pontine Glioma", "Refractory Ependymoma", "Refractory Medulloblastoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Conventional Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Diffusion Tensor Imaging", "type": "PROCEDURE" }, { "name": "Diffusion Weighted Imaging", "type": "PROCEDURE" }, { "name": "Dynamic Contrast-enhanced MR Perfusion", "type": "PROCEDURE" }, { "name": "Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Spectroscopic Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 71, "start_date": "2015-06-03", "completion_date": "2027-01-16", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-07T21:30:57.277Z", "location_count": 11, "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02359565" }, { "nct_id": "NCT06838676", "title": "ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Intrinsic Pontine Gliomas (DIPG)", "Progressive DIPG", "Refractory DIPG", "Recurrent DIPG", "H3K27-altered High Grade Glioma" ], "interventions": [ { "name": "ACT001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "39 Years", "sex": "ALL", "summary": "12 Months to 39 Years" }, "enrollment_count": 60, "start_date": "2025-07-10", "completion_date": "2035-07", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-07T21:30:57.277Z", "location_count": 12, "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 9 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06838676" }, { "nct_id": "NCT06482905", "title": "Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "High-grade Glioma", "WHO Grade Ⅳ Glioma" ], "interventions": [ { "name": "Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Tcelltech Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 52, "start_date": "2024-09-04", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-10-07T21:30:57.277Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06482905" }, { "nct_id": "NCT00100880", "title": "Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Atypical Teratoid/Rhabdoid Tumor", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Ependymoblastoma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebellar Astrocytoma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Infratentorial Ependymoma", "Childhood Low-grade Cerebellar Astrocytoma", "Childhood Low-grade Cerebral Astrocytoma", "Childhood Medulloepithelioma", "Childhood Mixed Glioma", "Childhood Oligodendroglioma", "Childhood Supratentorial Ependymoma", "Recurrent Childhood Brain Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma" ], "interventions": [ { "name": "lenalidomide", "type": "DRUG" }, { "name": "perfusion-weighted magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "diffusion-weighted magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 45, "start_date": "2004-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-10-07T21:30:57.277Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00100880" }, { "nct_id": "NCT04541225", "title": "Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Glioma, Malignant", "Glioma, Mixed", "Glial Cell Tumors", "Breast Cancer", "Breast Carcinoma", "Cancer of Breast", "Cancer of the Breast", "Breast Tumor", "Malignant Tumor of Breast", "Advanced Breast Cancer", "Advanced Breast Carcinoma", "Metastatic Breast Cancer", "Metastatic Breast Carcinoma", "Prostate Cancer", "Prostatic Cancer", "Cancer of Prostate", "Cancer of the Prostate", "Prostate Neoplasm", "Castrate Resistant Prostate Cancer", "Castration-resistant Prostate Cancer", "Castration Resistant Prostatic Neoplasms", "Glioblastoma", "Recurrent Glioblastoma" ], "interventions": [ { "name": "NUV-422", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2020-12-08", "completion_date": "2022-08-31", "has_results": false, "last_update_posted_date": "2023-07-14", "last_synced_at": "2026-10-07T21:30:57.277Z", "location_count": 12, "location_summary": "Tucson, Arizona • Miami, Florida • Boston, Massachusetts + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04541225" } ] }